July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Systemic and intraocular administration of the liposomal formulation of the cyclic GMP analogue CN03: An exploratory safety and tolerability study in non-human primates
Author Affiliations & Notes
  • Francois Paquet-Durand
    Experimental Ophthalmology, Institute for Ophthalmic Research, Tuebingen, Germany
  • Tobias Peters
    Centre for Ophthalmology, University Hospital Tuebingen, Tuebingen, Germany
  • Pieter Gaillard
    2-BBB medicines BV, Leiden, Netherlands
  • Nicolaas Schipper
    RISE, Södertälje, Sweden
  • Torsten Strasser
    Experimental Ophthalmology, Institute for Ophthalmic Research, Tuebingen, Germany
  • Frank Schwede
    Biolog Life science Institute, Bremen, Germany
  • Valeria Marigo
    Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
  • Per A R Ekstrom
    Clinical Sciences Lund, Lund University, Lund, Sweden
  • Christer Säfholm
    Comparative Medicine, Karolinska Institute, Stockholm, Sweden
  • Footnotes
    Commercial Relationships   Francois Paquet-Durand, Mireca Medicines GmbH (I); Tobias Peters, None; Pieter Gaillard, 2-BBB Medicines BV (E), Mireca Medicines GmbH (I); Nicolaas Schipper, None; Torsten Strasser, None; Frank Schwede, Biolog life science institute (E); Valeria Marigo, Mireca Medicines GmbH (I); Per Ekstrom, Mireca Medicines GmbH (I); Christer Säfholm, None
  • Footnotes
    Support  European Union, FP7: HEALTH-F2-2012-304963
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 257. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Francois Paquet-Durand, Tobias Peters, Pieter Gaillard, Nicolaas Schipper, Torsten Strasser, Frank Schwede, Valeria Marigo, Per A R Ekstrom, Christer Säfholm; Systemic and intraocular administration of the liposomal formulation of the cyclic GMP analogue CN03: An exploratory safety and tolerability study in non-human primates. Invest. Ophthalmol. Vis. Sci. 2019;60(9):257.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : The cGMP analogue CN03 targets cGMP signalling, a disease driver common to different types of retinal degeneration. For efficient targeting to the neuroretina CN03 was combined with a liposomal (LP) drug delivery system. In rodents, LP-CN03 has shown significant photoreceptor protection and preservation of in vivo retinal function, without major adverse events. The objective of the study was to determine the toxicity of CN03 and LP-CN03, following intravitreal (IVT) or intravenous (IV) administration. IVT administration is the intended human therapeutic route, IV injection was tested to investigate systemic toxicity.

Methods : Cynomolgus monkeys were assigned to five different groups, consisting of one male and one female (n=2). Group 1 served as saline control for IVT and IV dosing, group 2 served as liposome (LP) control. Groups 3 and 4 received IVT injections of either 1X or 10X of the intended therapeutic dose, of either LP-CN03 (left eye) or CN03 (right). Group 5 received 100X IV bolus injections of LP-CN03 (Day 1) and CN03 (Day 25). Toxicity was assessed based on clinical observations, body weights, ophthalmology, intraocular pressure (IOP), electroretinography (ERG), and clinical and anatomic pathology.

Results : IVT administration of LP caused transient white opacity in the vitreous body of all treated eyes, related to the milky consistency of LP. IVT injection of 1X and 10X CN03 was well-tolerated and only showed temporary pupil dilation in one male. IVT injection of 1X and 10X LP-CN03 was additionally associated with particles in the anterior chamber and vitreous body. At 10X, pigmented dots were also noted in the anterior lens capsule. IV injection of 100X LP-CN03 and CN03 was well tolerated and did not cause systemic toxicity. Comparison of pre- and post-dosing ERG did not reveal significant differences (p>0.05) in any of the groups, nor were there any indications of pathological changes in retinal morphology.

Conclusions : IVT injection of CN03 and LP-CN03 at the intended therapeutic dose was not associated with any changes in ophthalmoscopy, electroretinography or histopathology, and only revealed slight pupil dilation in one animal. IV slow bolus injection at 100X the intended therapeutic dose was well tolerated.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.